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Introduction: Genotyping for driver mutations is now routinely used 
to guide clinical care of patients with lung cancer. Adenosquamous 
lung carcinoma (AdSqLC) is a subtype of cancer that contains both 
adenocarcinoma and squamous cell carcinoma. However, the inci-
dence, clinicopathologic characteristics, and prognostic implications 
of major driver mutations in AdSqLCs are not well established.
Methods: Seventy-six resected AdSqLCs and 646 lung adenocarci-
nomas were screened for known genetic alterations involving EGFR, 
ERBB2, KRAS, BRAF, PIK3CA, AKT1, RET, and ALK. Tumors show-
ing acinar, lepidic, micropapillary, or papillary growth in glandular 
component were classified as classical AdSqLC.
Results: Of the 76 AdSqLCs, 43 (56.6%) harbored known mutant 
kinases, including 24 (31.6%) with EGFR mutations, eight (10.5%) 
with KRAS mutations, two (2.6%) with AKT1 (2.6%) mutations, one 
(1.3%) with ERBB2 insertion mutation, one (1.3%) with PIK3CA 
mutation, four (5.3%) with ALK fusions, and three (4%) with KIF5B-
RET fusions. No mutation was found in BRAF. The mutational profiles 
and clinicopathologic characteristics of classical AdSqLC were strik-
ingly similar to that of poorly differentiated adenocarcinoma. However, 
AdSqLCs with solid growth pattern in glandular component had high 
frequency of ALK or RET fusions and low EGFR  mutation rate.
Conclusions: To our knowledge, this is the first comprehensive study 
investigating major oncogenic driver mutations in a large cohort of 
AdSqLC patients in a Chinese population. The findings suggest that 
it will be clinically valuable to investigate the growth pattern of glan-
dular component in AdSqLCs.
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Lung cancer is the most common cause of cancer-related death worldwide.1 Adenosquamous lung carcinoma (AdSqLC) is 
a subtype of non–small-cell lung cancer (NSCLC), account-
ing for 1.6% to 4.5% of lung cancers.2–4 According to World 
Health Organization classification, AdSqLC is defined as a 
carcinoma showing components of both adenocarcinoma and 
squamous cell carcinoma, with each component comprising 
at least 10% of the tumor.5 AdSqLCs have more aggressive 
behavior and worse prognosis than adenocarcinoma or squa-
mous cell carcinoma.6,7
One of the most important and promising treatment 
strategies for NSCLC involves the subdivision of tumors into 
clinically relevant molecular subsets, using a classification 
based on the presence or absence of known so-called driver 
mutations, including EGFR, ERBB2, KRAS, BRAF, PIK3CA, 
AKT1, RET, and ALK.8,9 EGFR tyrosine kinase inhibitors are 
currently recommended as the first-line option for patients 
with EGFR-sensitizing mutations in the metastatic setting. In 
addition and more recently, crizotinib has been recommended 
as first-line systemic therapy for patients with advanced ALK-
rearranged NSCLC.10 Mutations in ERBB2, PIK3CA, BRAF, 
RET, MEK1, and AKT1 also define subsets of NSCLCs that 
may be amenable to treatment with other specific kinase 
inhibitors.8,9 A few studies with small sample size found that 
the frequency of EGFR mutation in AdSqLCs ranged from 
15% to 44% in East Asian population.11–14 However, whether 
AdSqLCs harbor other mutations and details of their preva-
lence are still largely unknown. With an estimated 1,608,800 
new cases of lung cancer per year worldwide in 2005, this 
equates to more than 25,000 new adenosquamous lung tumors 
per year,1 thus clarifying that mutation status could have thera-
peutic implications.
Because the understanding of genetic bases of AdSqLC 
is limited, there is no standard treatment currently available 
for the disease. AdSqLCs had a relatively high frequency of 
EGFR mutation,11–14 which is one of characteristics of lung 
adenocarcinoma and thereby most clinicians are prone to 
treat them as lung adenocarcinoma. By microdissection, pre-
vious studies found that AdSqLC is a heterogeneous disease 
with two cell components each of which carried the same 
EGFR mutations, suggesting that the tumors are relatively 
clonal.11,13 In addition, a recent study reported that a female 
AdSqLC patient with EGFR activating mutation treated with 
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gefitinib showed a complete response lasting 3 years.15 Thus, 
it is hypothesized that AdSqLC and adenocarcinoma origi-
nate from common cancer stem cells. Poorly differentiated 
lung adenocarcinomas also showed very aggressive clini-
cal course than moderate/well-differentiated adenocarcino-
mas.16,17 However, it remains unclear whether AdSqLCs have 
mutation profiles and clinicopathologic characteristics simi-
lar to poorly differentiated adenocarcinomas.
In most AdSqLCs, glandular component shows acinar, 
lepidic, micropapillary, or papillary growth pattern.18 It is 
also noted that some of tumors showed solid growth pattern 
in glandular component.4 Previous studies demonstrated that 
majority of ALK-rearranged lung adenocarcinomas showed 
a solid growth pattern. In contrast, only a small percentage 
of ALK wild-type tumors showed solid growth.19,20 In our pre-
vious work, we also found that 73% of RET-rearranged lung 
adenocarcinomas showed solid pattern.21 A squamous cell 
carcinoma marker, TP63, was expressed in a majority of ALK-
rearranged adenocarcinomas. However, staining of TP63 was 
seen in a minority of adenocarcinomas (9%–32%), suggesting 
that its expression in ALK-rearranged tumor might not be sim-
ply aberrant.20,22,23 The p63 transcription factor (TP63) plays 
a critical role in squamous cell carcinoma, which is a master 
regulator of squamous cell differentiation.22 It is interesting 
to note that some of AdSqLCs can show both solid and squa-
mous component (TP63-positive). Its mutational characteris-
tics are unknown.
Here we examined the mutational status of EGFR, 
KRAS, ERBB2, BRAF, PIK3CA, AKT1, RET, and ALK in a 
cohort of 76 Chinese patients with resected AdSqLCs. We also 
compared the clinicopathologic and mutational characteristics 
between 76 AdSqLCs and 646 lung adenocarcinomas.
MATERIALS AND METHODS
Specimen Collection
During the period from October 2002 to June 2012, an 
overall of 2195 patients were treated surgically for primary 
lung cancer in the Department of Thoracic Surgery of Fudan 
University Shanghai Cancer Center. Of these, we identified 
76 (3.4%) with AdSqLC. Fifty-five patients had both frozen 
and corresponding formalin-fixed paraffin-embedded (FFPE) 
tumor tissues. For 21 patients diagnosed before October 2007, 
only FFPE tissues were available.
From October 2007 to August 2011, a total of 646 
patients with lung adenocarcinoma were also operated on for 
a primary tumor, including 23 patients (3.5%) who during sur-
gery were found unexpectedly to have pleural metastasis. For 
these cases, only biopsy samples of the metastatic sites were 
collected.
A consent form was signed by every patient or legal 
representative. The study was approved by the Committee 
for Ethical Review of Research at Shanghai Cancer Hospital. 
Medical records of all patients were reviewed to extract data 
on clinicopathologic characteristics, including sex, age, 
smoking history, stage, and treatment history. Patients were 
followed up in clinic or by telephone for disease recurrence 
and survival.
Tumor Pathology and Mutational Analyses
Each case was reviewed and both squamous and glan-
dular components in at least 10% of the tumor by light 
microscope were confirmed by two pathologists (Drs. Li 
and Shen) after histologic diagnosis based on World Health 
Organization criteria.5 Squamous component showing iden-
tifiable keratinization, pearl formation, and/or intercellular 
bridges is required for the diagnosis. Histological subtypes 
of glandular component were determined by the new 
International Association for the Study of Lung Cancer/
ATS/ERS multidisciplinary classification.21 Tumors show-
ing acinar, lepidic, micropapillary, or papillary growth 
pattern glandular component were diagnosed as classical 
AdSqLC. The proportion of glandular and squamous com-
ponents in classical AdSqLC was identified by microscopic 
examination. The diagnosis of AdSqLC showing solid 
growth pattern in glandular component was also verified by 
immunohistochemical biomarkers (TTF-1, CK7, Napsin A, 
CK5/6, and/or p63).
The mutational status of EGFR (exons18–21), ERBB2 
(exon 20), KRAS (exons 2–3), BRAF (exons 11–15), and 
AKT1 (exon 4) was determined using polymerase chain reac-
tion–based direct sequencing and verified by DNA sequenc-
ing analysis. For detection of ALK and RET fusions, primers 
were designed to amplify all known fusion variants with the 
use of cDNA (Supplementary Table 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A453). All mutations 
were verified by analysis of an independent polymerase chain 
reaction isolate.
To study further the glandular and squamous compo-
nents of tumors by microdissection, clearly distinguishable 
AdSqLCs were next studied, which included the following 
criteria: tumors harboring a mutation; tumor specimen con-
taining a minimum of 50% tumor cells to ensure adequate 
material; and corresponding normal tissue also being avail-
able for analysis. To avoid the contamination of one cell com-
ponent by the other, samples with two cell components that 
intermingled on histologic examination were excluded.
Fluorescence In Situ Hybridization
As previously described,24 ALK rearrangements were 
detected in FFPE specimens with the use of a commercially 
available break-apart probe for the ALK gene (Vysis LSI ALK 
Dual Color; Abbott Molecular, Abbott Park, IL).
Statistical Analysis
Data were analyzed using the Statistical Package 
for the Social Sciences Version 16.0 Software (SPSS Inc., 
Chicago, IL) or Prism 5.0 (Graph Pad Software Inc., La 
Jolla, CA). Relapse-free survival (RFS) and overall survival 
(OS) data of AdSqLC patients diagnosed from June 2007 to 
August 2011 were included and compared with data from 
lung adenocarcinoma patients diagnosed from April 2008 to 
April 2010. The Kaplan–Meier method was used to estimate 
RFS and OS, and the differences were compared using the 
log-rank test. The two-sided significance level was set at a 
p value less than 0.05.
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RESULTS
Patient Characteristics
A total of 76 AdSqLCs from a Chinese population were 
studied. All cases were rereviewed by the two pathologists for 
confirmation of tumor histology. The characteristics of these 
AdSqLCs are listed in Supplementary Table 2 (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A454). There are 
more smokers in AdSqLC than in adenocarcinoma (p < 0.0001).
Spectrum of Mutations
Tumor specimens containing both components were 
studied in mutational analysis; 56.6% (43 of 76) harbored 
known mutant kinases. Mutations in the EGFR kinase domain 
were observed in 31.6% tumors (24 of 76). One tumor harbored 
both exon 19 deletion and PIK3CA mutations. The remaining 
19 tumor-carrying mutations included eight with KRAS muta-
tion, four with ALK fusion, two with AKT1 mutation, one with 
ERBB2 mutation, three with KIF5B-RET fusion, and one with 
PIK3CA mutation. No mutation was found in BRAF. Of the 
samples 43.4% (33 of 76) did not harbor mutations in EGFR, 
KRAS, ALK, ERBB2, PIK3CA, AKT1, RET, or BRAF (Fig. 1).
There was a significantly higher rate of EGFR muta-
tions in never smokers (51.5% versus 16.3 %; p = 0.001). 
EGFR mutations were found more frequently in tumors larger 
than 3 cm (41.3% versus 16.7%; p = 0.024; Supplementary 
Table 3, Supplemental Digital Content 3, http://links.lww.
com/JTO/A455). The clinicopathologic characteristics of indi-
vidual patients with EGFR/ERBB2/KRAS/BRAF/PIK3CA/
AKT1 mutations and ALK/RET fusions are summarized in 
Supplementary Table 4 (Supplemental Digital Content 4, 
http://links.lww.com/JTO/A456).
Of 24 EGFR kinase domain mutations, there were 
two exon 20 insertion mutations and one T790M mutation, 
which can confer resistance to gefitinib/erlotinib treatment. 
Six of eight KRAS mutations (75%) were found in smokers 
and 87.5% of patients with KRAS mutation were men. We 
also found that three of four ALK fusions (75%) were found 
in smokers
.
Mutational and Clinicopathologic 
Characteristics of AdSqLCs
Fifty-three of 76 AdSqLCs (69.7%) showing acinar, 
lepidic, micropapillary, or papillary glandular growth pat-
terns were classified as classical AdSqLCs. Representative 
microscopic images of histologic subtypes of glandular com-
ponent in AdSqLCs are shown in Supplementary Figure 1 
(Supplemental Digital Content 5, http://links.lww.com/JTO/
A4570). Of the patients with classical AdSqLC, 69.8% (37 
of 53) were men and 51% (27 of 53) were smokers. The pro-
portion of two cell components was available in 48 samples. 
The frequency of EGFR mutations in glandular-dominant 
AdSqLCs (glandular component ≥50%) was significantly 
higher than that in squamous-dominant tumors (squamous 
component ≥50%; 80% versus 24.2%; p < 0.0001), whereas 
KRAS, AKT1, and PIK3CA mutations were all found in squa-
mous-predominant AdSqLCs (Fig. 2A).
We further found that driver mutation profiles were quite 
similar between classical AdSqLCs and poorly differentiated 
lung adenocarcinomas (Fig. 2). There were no significant dif-
ferences between classical AdSqLCs and poorly differenti-
ated lung adenocarcinomas regarding frequency of EGFR or 
KRAS mutations (Table 1). We also found that the frequency 
of EGFR mutation in AdSqLCs was significantly lower than in 
adenocarcinomas (61.6% versus 31.6%; p < 0.0001).
Twenty-three of 76 AdSqLCs (30.3%) showed solid 
growth pattern in glandular component (Table 2). The fre-
quency of fusion genes (RET and ALK) was surprisingly higher 
FIGURE 1.  Frequency of driver mutations among adenosquamous lung carcinomas (AdSqLCs) and lung adenocarcinomas.
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in AdSqLCs with solid growth glandular component than that 
with classical glandular component (30.4% versus 0%). The 
mutation rate of EGFR for AdSqLC with solid growth glan-
dular component was only 4.3%, lower than that for classical 
AdSqLC (41.3%; p = 0.001; Table 1).
Mutational Analysis in Microdissected 
Classical AdSqLCs
Thirty-two of 53 classical AdSqLCs (60.4%) harbored 
mutations in one of the tested genes, and 16 (58.6%) of these 
were excluded from microdissection analysis. These included 
FIGURE 2.  Frequency of driver mutations in classical AdSqLCs (C-AS) and AdSqLCs with solid growth pattern glandular com-
ponent (solid type AS) and lung adenocarcinoma. A. Frequency of driver mutations according to the proportion of glandular 
component; glandular-dominant AdSqLCs (glandular component ≥50%); squamous-dominant tumors (squamous component 
≥50%). B. Frequency of driver mutations in classical AdSqLCs, adenosqumous lung carcinoma with solid growth pattern glan-
dular component (solid type AS), poorly, moderately, and well-differentiated adenocarcinoma (ADC poor, ADC-M, and ADC-W). 
AdSqLCs, adenosquamous lung carcinoma, ADC, adenocarcinoma.
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10 samples with tumor content less than 50%, three with two 
cell components intermingled on histologic examination, 
and three with insufficient tissue. It was possible to perform 
microdissection on 13 tumors, including eight with EGFR 
mutations (1 case with an EGFR synonymous mutation, 
T790T), three with KRAS mutations, one with double muta-
tions (EGFR and PIK3CA), and one with ERBB2 mutation. 
In nine of the 13, same mutation was found in both histologic 
components, whereas in four cases, mutations were found 
only in the glandular component, including two KRAS muta-
tions (cases 4 and 30), one HER2 mutation (case 36; Fig. 3), 
and one synonymous EGFR mutation (G2370A; T790T).
Clinical Outcomes
The survival data were available in 58 AdSqLCs and 246 
lung adenocarcinomas. Twenty-nine of 58 AdSqLC patients 
(50%) died during the follow-up. After surgery, nine of 22 
patients (41%) with EGFR mutations are still relapse-free and 
13 (59%) experienced a relapse. There were no significant 
differences in RFS or OS for AdSqLC patients with EGFR 
mutations compared with those with KRAS, ALK, or wild-type 
(Supplementary Figure 1, Supplemental Digital Content 5, 
http://links.lww.com/JTO/A4570). The 2-year OS for patients 
with EGFR mutations was 51.3% (95% confidence inter-
val, 32%–83.6%). Patients with ALK rearrangements had a 
longer OS as compared with patients with KRAS mutations 
(p = 0.027). The number of AKT1, ERBB2, RET, and PIK3CA 
mutations were too small for further analysis.
We further compared the RFS and OS for patients with 
AdSqLCs and adenocarcinomas. There were no significant 
differences in RFS among patients with classical AdSqLC, 
poorly differentiated lung adenocarcinomas, and AdSqLCs 
with solid growth glandular component, but they all showed 
a worse OS compared with moderately to well-differentiated 
adenocarcinomas (Fig. 4).
DISCUSSION
It is becoming evident that subsets of NSCLC can be 
further defined at the molecular level by specific driver muta-
tions that play a crucial role in tumor transformation. Such 
mutations have been found to occur in EGFR, ERBB2, KRAS, 
BRAF, PIK3CA, AKT1, RET, and ALK. These mutations have 
been widely studied mainly in lung adenocarcinomas. EGFR, 
ERBB2, KRAS, BRAF, and ALK mutations are much more 
frequent in adenocarcinomas than in squamous cell carcino-
mas,21 whereas PIK3CA mutations occur more frequently in 
TABLE 1.  Clinical Characteristics of Patients with Classical, Solid Growth Glandular Adenosquamous Lung Carcinomas and 
Lung Adenocarcinomas
Characteristic
Classical AdSqLCs  
(N = 53)
AdSqLCs—Solida  
(N = 23)
Poorly Differentiated ADCs 
(n = 219)
M-W Differentiated ADCs  
(n = 427)
No. % No. % p No. % p No. % p
Age, yrs
  <60 27 50.9 10 43.5 0.726 115 52.5 0.564 220 51.5 0.636
  ≥60 26 49.1 13 56.5 104 47.5 207 48.5
Sex
  Male 37 69.8 19 82.6 0.263 137 62.6 0.419 159 37.2 <0.0001
  Female 16 30.2 4 17.4 82 37.4 268 62.8
Smoking history
  Never 26 49 7 30.4 0.217 105 48 0.791 311 72.8 <0.0001
  Ever 27 51 16 69.6 114 52 116 27.2
Stage
  I–II 25 47.2 12 52.2 0.737 93 42.5 0.490 304 71.2 0.001
  III–IV 28 52.8 11 47.8 126 57.5 123 28.8
Location
  Central 14 26.4 9 39.1 0.288 / / / / / /
  Peripheral 39 73.6 14 60.9 / / / / / /
EGFR mutation
  Present 23 43.4 1 4.3 0.001 92 42.0 0.965 306 71.7 <0.0001
  Absent 30 56.6 22 95.7 127 58.0 121 28.3
KRAS mutation
  Present 5 9.4 3 13.0 0.708 28 12.8 0.652 20  4.7 0.092
  Absent 48 90.6 20 87.0 191 87.2 407 95.3
RET and ALK fusion
  Present 0 0 7 30.4 / 16  7.3 / 31  7.3 /
  Absent 53 100 16 69.6 203 92.7 396 92.7
aAdenosquamous lung carcinoma with solid growth pattern in glandular component.
AdSqLC, adenosquamous lung carcinoma; ADC, adenocarcinoma; M-W Differentiated ADCs, moderately and well-differentiated adenocarcinomas.
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squamous cell carcinomas25 and AKT1 mutations have been 
identified only in squamous cell carcinomas.26 A few studies 
have reported the frequency of EGFR and KRAS mutations in 
a limited number of AdSqLCs and that ALK fusions were also 
found incidentally, but did not note the status of other driver 
mutations.11–14,27 Here we delineate, for the first time, profiles 
of the major known driver mutations and their clinicopatho-
logic characteristics in a large cohort of AdSqLCs in Chinese 
patients.
Prior studies found that EGFR mutation rate for 
AdSqLCs ranged from 15.4% to 44%, higher than that for 
squamous cell carcinoma, but less for adenocarcinoma.11,13,14,27 
Therefore, it seems reasonable to assume that AdSqLC is a mix 
of various proportions of adenocarcinoma and squamous cell 
carcinomas. Our study showed that the frequency of EGFR 
mutation in AdSqLCs was significantly lower than in adeno-
carcinomas, which was consistent with prior studies.11,13,14,27 
However, other gene mutations (KRAS, ALK, RET, PIK3CA, 
and AKT1) in AdSqLCs showed frequency comparable to that 
in adenocarcinomas. Our results can help explain the incon-
sistency of mutation profiles between adenocarcinoma and 
AdSqLC. We found that clinicopathologic and mutational 
characteristics of patients with classical AdSqLC were strik-
ingly similar to that of poorly differentiated adenocarcinomas.
The similar characteristics indicate that the two sub-
types may share a common mechanism of pathogenesis. In 
our study, with the use of strict criteria for confident microdis-
section, 12 of 29 classical AdSqLCs with mutations (41.4%) 
were included for microdissection analysis. Similar to previ-
ous results,11,13 all activating EGFR mutations and one KRAS 
mutation were present in both glandular and squamous com-
ponents. These findings indicate that both adenocarcinomas 
and AdSqLCs may arise from undifferentiated adenocarci-
noma stem cells, which are capable of differentiating into 
adenocarcinomas and a few of them have the potential to give 
rise to both adeno- and squamous cell components. AdSqLCs 
might still keep their undifferentiated cancer stem cells or 
poorly differentiated characteristics. However, we still have 
few clues as to the pathogenesis of AdSqLCs; further studies 
on transformation mechanisms of AdSqLCs are needed.
Patients with classical AdSqLCs shared an EGFR 
mutation rate similar to that of poorly differentiated 
TABLE 2.  Clinical Details of 23 Adenosquamous Lung Carcinomas with Solid Growth Pattern in Glandular Component
Cases Age/Sex Smoking Stage Mutations
Glandular Component Squamous Component
TTF-1 p63 Napsin A CK7 TTF-1 p63
ALK
  24 59/M Smoker IIIA EML4-ALK + - / / − +
  27 59/F Never IIIA KIF5B-ALK + - + + − +
  41 64/M Smoker IIB EML4-ALK + - / / − +
  49 56/M Smoker IIIA EML4-ALK + - + + − +
RET
  48 72/M Smoker IIIA KIF5B-RET + - + + − +
  74 73/M Never IIB KIF5B-RET + + + + + +
  68 46/F Never IIA KIF5B-RET + - / + − +
KRAS
  45 62/M Smoker IIIA G12V - - + + − +
  66 43/M Smoker IIIA G12C + - / + − +
  67 44/M Smoker IIIA G12C + - / + − +
EGFR
  10 49/F Never IIA 770–771 ins H + - / / − +
Wild-type
  12 64/M Never IIb No - - / + − +
  17 62/M Smoker IIa No + - / / − +
  18 58/M Smoker IIIA No + - / / − +
  23 54/M Smoker IIIA No + - / / − +
  26 62/M Smoker IIIb No + - / + − +
  29 71/M Never IIIb No + - / + − +
  32 50/M Smoker IIb No + - / / − +
  44 67/M Never Ia No + - / / − +
  57 76/M Smoker Ia No + - / − − +
  70 82/M Never IA No − - + − +
  72 69/F Smoker IIIA No + - - - − +
  76 66/M Smoker IB No + - / + − +
M, male; F, female; ins, insertion.
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adenocarcinoma. Because glandular component in classical 
AdSqLC is morphologically so different from that of squa-
mous component, the relative proportion of glandular and 
squamous components can be easily identified. Thereby we 
found that 90% EGFR mutations (18 of 20) presented in 
tumors with a glandular component higher than 20%, rarely 
in squamous predominant (>70%) or AdSqLCs. We also 
found that ALK and RET fusions were identified in 30.4% of 
AdSqLCs with solid growth in glandular component, whereas 
EGFR mutations were only found in 4.3%. These findings 
suggested that the identification of subtypes and proportion 
of glandular component in AdSqLC would allow clinicians to 
select patients who are most likely to benefit from targeted 
therapy.
To date there is little information concerning 
KRAS/ERBB2 mutation-driven AdSqLC. Only seven KRAS 
mutations were found in prior studies (3 in Western and 4 in 
Asian populations) and no ERBB2 insertion mutation was 
identified in AdSqLCs.11–13,27 In our study, we identified eight 
AdSqLCs that harbored KRAS mutation. Of these, three were 
identified as solid-type AdSqLC, and five were classified as 
classical AdSqLC. Three of them with KRAS mutation (2 
with lepidic and 1 with papillary pattern in glandular compo-
nent) were microdissected. It was very interesting that KRAS 
FIGURE 3.  Heterogeneous 
distribution of driver mutations in 
glandular and squamous com-
ponents. A, Case 30, top, tumor 
field containing glandular and 
squamous subtypes of adenosqua-
mous tumor (magnification, ×40). 
Middle, H&E stain (magnification, 
×200). Bottom: sequencing chro-
matograms showing KRAS muta-
tion (c.34, G ≥ T, G12C) only in 
the glandular component. B, Case 
36, top, tumor field of glandular 
(left) and squamous component 
(right) of adenosquamous tumor 
(magnification, ×40). Middle, 
H&E stain (magnification, ×200). 
Bottom: sequencing chromato-
grams showing ERBB2 insertion 
only in the glandular component. 
AC, adenous carcinoma (glandu-
lar component); SC, squamous 
component; H&E, hematoxylin 
and eosin.
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mutation only presented in glandular component, not in the 
squamous component in two tumors with lepidic growth pat-
tern, and both components harbored KRAS mutation in another 
tumor with acinar component. KRAS-driven lepidic compo-
nent (formerly known as bronchioloalveolar carcinoma) is a 
carcinoma in situ, whereas squamous cell component without 
KRAS mutation is an invasive carcinoma. It seems plausible 
that they might result from a collision of adenocarcinoma and 
squamous cell carcinoma. However, both ERBB2-driven glan-
dular component and ERBB2-negative squamous component 
were invasive carcinomas, which may result from subclonal 
heterogeneity. The two components might derive from com-
mon ERBB2-negative cancer stem cells, and subclones devel-
oping ERBB2 mutation form glandular components whereas 
cells without ERBB2 mutation evolve into squamous carci-
nomas. Prior study demonstrated that heterogeneous EGFR 
mutations in adenocarcinoma were because of heterogeneous 
amplification of a mutated allele and low sensitivity of direct 
sequencing.28 Although only classical AdSqLCs with tumor 
cell content higher than 50% were selected for microdissec-
tion, we do not exclude the possibility that heterogeneous 
distribution of KRAS and ERBB2 mutations in AdSqLCs may 
result from technical artifact of direct sequencing.
Finally, our results demonstrated that classical AdSqLC 
shared clinicopathologic and mutational characteristics very 
similar to those of poorly differentiated adenocarcinoma. We 
also found that classical AdSqLC patients had a worse OS com-
pared with patients with poorly differentiated adenocarcinoma, 
indicating that relapsed classical AdSqLCs may have more 
aggressive behavior and respond poorly to current therapies. 
However, studies with a much larger sample size and longer 
duration of follow-up are still necessary to confirm these results.
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